Literature DB >> 18417046

Nonalcoholic fatty liver disease as a component of the metabolic syndrome.

Mouen A Khashab1, Suthat Liangpunsakul, Naga Chalasani.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an important cause of liver-related morbidity and mortality. The association between NAFLD and the metabolic syndrome is well established: the presence of the metabolic syndrome signifies advanced histology in NAFLD patients. Emerging data indicate that patients with NAFLD have a significantly higher prevalence of cardiovascular disease. This article reviews the definitions of the two syndromes, their association, and the cardiovascular risk conferred by both when they occur separately and together. This review also discusses management options for the syndromes, including treating the individual components of the metabolic syndrome in NAFLD patients.

Entities:  

Mesh:

Year:  2008        PMID: 18417046     DOI: 10.1007/s11894-008-0012-0

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  47 in total

Review 1.  Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.

Authors:  J Vlachogiannakos; A K Tang; D Patch; A K Burroughs
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

2.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

Review 3.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

4.  Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.

Authors:  Hellan Kang; Joel K Greenson; Jason T Omo; Cewin Chao; Debra Peterman; Lilian Anderson; Laura Foess-Wood; Mary A Sherbondy; Hari S Conjeevaram
Journal:  Am J Gastroenterol       Date:  2006-10       Impact factor: 10.864

5.  Metformin in non-alcoholic steatohepatitis.

Authors:  G Marchesini; M Brizi; G Bianchi; S Tomassetti; M Zoli; N Melchionda
Journal:  Lancet       Date:  2001-09-15       Impact factor: 79.321

6.  Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery.

Authors:  Kevin B Barker; Nicole A Palekar; Steven P Bowers; Joel E Goldberg; Joseph P Pulcini; Stephen A Harrison
Journal:  Am J Gastroenterol       Date:  2006-02       Impact factor: 10.864

7.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

8.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

Authors:  Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Yoshihiko Tokusashi; Naoyuki Miyokawa; Kimihide Nakamura
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

9.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

Authors:  Naga Chalasani; Hisham Aljadhey; Joe Kesterson; Michael D Murray; Stephen D Hall
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

10.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

View more
  28 in total

Review 1.  Current and Future Burden of Chronic Nonmalignant Liver Disease.

Authors:  Prowpanga Udompap; Donghee Kim; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

Review 2.  Systemic inflammation, metabolic syndrome and progressive renal disease.

Authors:  Pietro Cirillo; Yuri Y Sautin; John Kanellis; Duk-Hee Kang; Loreto Gesualdo; Takahiko Nakagawa; Richard J Johnson
Journal:  Nephrol Dial Transplant       Date:  2009-02-10       Impact factor: 5.992

Review 3.  Non-alcoholic fatty liver disease - the heart of the matter.

Authors:  Haneen Azzam; Stephen Malnick
Journal:  World J Hepatol       Date:  2015-06-08

4.  Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.

Authors:  Pierre Johansen; Daniel Howard; Ryan Bishop; Søren Ilsøe Moreno; Kristine Buchholtz
Journal:  Pharmacoeconomics       Date:  2020-05       Impact factor: 4.981

5.  Creosote bush-derived NDGA attenuates molecular and pathological changes in a novel mouse model of non-alcoholic steatohepatitis (NASH).

Authors:  Lu Han; Stefanie Bittner; Dachuan Dong; Yuan Cortez; Hunter Dulay; Sara Arshad; Wen-Jun Shen; Fredric B Kraemer; Salman Azhar
Journal:  Mol Cell Endocrinol       Date:  2019-08-12       Impact factor: 4.102

Review 6.  Metabolic syndrome and hepatic resection: improving outcome.

Authors:  Shefali Agrawal; Cherag Daruwala
Journal:  HPB (Oxford)       Date:  2011-10-19       Impact factor: 3.647

Review 7.  Nonalcoholic fatty liver disease and the coronary artery disease.

Authors:  Sombat Treeprasertsuk; Francisco Lopez-Jimenez; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

8.  Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats.

Authors:  L Nikolaenko; Y Jia; C Wang; M Diaz-Arjonilla; J K Yee; S W French; P Y Liu; S Laurel; C Chong; K Lee; Y Lue; W N P Lee; R S Swerdloff
Journal:  Endocrinology       Date:  2013-11-26       Impact factor: 4.736

9.  Genetic factors for resistance to diet-induced obesity and associated metabolic traits on mouse chromosome 17.

Authors:  Carrie A Millward; Lindsay C Burrage; Haifeng Shao; David S Sinasac; Jean H Kawasoe; Annie E Hill-Baskin; Sheila R Ernest; Aga Gornicka; Chang-Wen Hsieh; Sorana Pisano; Joseph H Nadeau; Colleen M Croniger
Journal:  Mamm Genome       Date:  2009-01-10       Impact factor: 2.957

10.  Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARα-dependent and -independent pathways.

Authors:  Haiyan Zhang; Wen-Jun Shen; Yuan Cortez; Fredric B Kraemer; Salman Azhar
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-10-25       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.